This content is machine translated Endometrial Cancer Prolonged progression-free survival through combination therapy Endometrial cancer is the sixth most common cancer in women worldwide and has a poor prognosis, particularly in terms of long-term results. The median overall survival time is less than…
View Post 4 min This content is machine translated Non-resectable melanoma New triple therapy improves progression-free survival Both protein kinase inhibitors and ipilimumab/nivolumab combined have better efficacy than their respective monotherapies in patients with non-resectable melanoma. This has been known for some time. An interesting new approach…
View Post 2 min This content is machine translated Stage 2 analysis of the CLL11 study Is the chlorambucil combination with GA101 superior to that with rituximab? At the ASH Congress in New Orleans, one of the topics was the CLL11 Phase 3 trial. After showing in the last issue of InFo ONCOLOGY & HEMATOLOGY that the…
View Post 3 min This content is machine translated Follicular lymphoma Rituximab in maintenance monotherapy. A study presented at ASH 2013 in New Orleans examined the role of rituximab in maintenance therapy in patients with follicular lymphoma. The study showed that the drug, when applied…
View Post 6 min This content is machine translated Chronic lymphocytic leukemia and non-Hodgkin's lymphoma Updates on the active ingredients GA101 and rituximab Three studies on chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma were discussed at the ASH in New Orleans: One was an update on the stage 1 analysis of the CLL11…
View Post 4 min This content is machine translated Treatment of metastatic colorectal carcinoma. Patients with RAS wild type benefit in overall survival New data on first-line treatment of metastatic colorectal cancer were presented at the ASCO GI in San Francisco. The post-hoc analyses consistently confirm that RAS mutation status is an important…
